Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case–control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46–0.95], p = 0.0281), PFS (HR 0.65 [95% CI 0.48–0.89]; p = 0.0074) and higher disease control rates (DCR, 86.4% vs 67.5%, p = 0.0096), within the pembrolizumab cohort. No significant associations were found between FHC and OS/PFS/DCR within the chemotherapy cohort. We explored the association between FHC and somatic DNA damage response (DDR) gene alterations as underlying mechanism to our findings in a parallel cohort of 118 NSCLC, 16.9% of whom were FHC-high. The prevalence of ≥ 1 somatic DDR gene mutation was 20% and 24.5% (p = 0.6684) in FHC-high vs. FHC-low/negative, with no differences in tumor mutational burden (6.0 vs. 7.6 Mut/Mb, p = 0.6018) and tumor cell PD-L1 expression. FHC-high status identifies NSCLC patients with improved outcomes from pembrolizumab but not chemotherapy, independent of somatic DDR gene status. Prospective studies evaluating FHC alongside germline genetic testing are warranted.

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status / Cortellini, A; Giusti, R; Filetti, M; Citarella, F; Adamo, V; Santini, D; Buti, S; Nigro, O; Cantini, L; Di Maio, M; Aerts, Jgjv; Bria, E; Bertolini, F; Ferrara, Mg; Ghidini, M; Grossi, F; Guida, A; Berardi, R; Morabito, A; Genova, C; Mazzoni, F; Antonuzzo, L; Gelibter, A; Marchetti, P; Chiari, R; Macerelli, M; Rastelli, F; Della Gravara, L; Gori, S; Tuzi, A; De Tursi, M; Di Marino, P; Mansueto, G; Pecci, F; Zoratto, F; Ricciardi, S; Migliorino, Mr; Passiglia, F; Metro, G; Spinelli, Gp; Banna, Gl; Friedlaender, A; Addeo, A; Ficorella, C; Porzio, G; Tiseo, M; Russano, M; Russo, A; Pinato, Dj.. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - 15:1(2022), p. 9. [10.1186/s13045-022-01226-2]

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Buti S;Tiseo M;
2022

Abstract

Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case–control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46–0.95], p = 0.0281), PFS (HR 0.65 [95% CI 0.48–0.89]; p = 0.0074) and higher disease control rates (DCR, 86.4% vs 67.5%, p = 0.0096), within the pembrolizumab cohort. No significant associations were found between FHC and OS/PFS/DCR within the chemotherapy cohort. We explored the association between FHC and somatic DNA damage response (DDR) gene alterations as underlying mechanism to our findings in a parallel cohort of 118 NSCLC, 16.9% of whom were FHC-high. The prevalence of ≥ 1 somatic DDR gene mutation was 20% and 24.5% (p = 0.6684) in FHC-high vs. FHC-low/negative, with no differences in tumor mutational burden (6.0 vs. 7.6 Mut/Mb, p = 0.6018) and tumor cell PD-L1 expression. FHC-high status identifies NSCLC patients with improved outcomes from pembrolizumab but not chemotherapy, independent of somatic DDR gene status. Prospective studies evaluating FHC alongside germline genetic testing are warranted.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status / Cortellini, A; Giusti, R; Filetti, M; Citarella, F; Adamo, V; Santini, D; Buti, S; Nigro, O; Cantini, L; Di Maio, M; Aerts, Jgjv; Bria, E; Bertolini, F; Ferrara, Mg; Ghidini, M; Grossi, F; Guida, A; Berardi, R; Morabito, A; Genova, C; Mazzoni, F; Antonuzzo, L; Gelibter, A; Marchetti, P; Chiari, R; Macerelli, M; Rastelli, F; Della Gravara, L; Gori, S; Tuzi, A; De Tursi, M; Di Marino, P; Mansueto, G; Pecci, F; Zoratto, F; Ricciardi, S; Migliorino, Mr; Passiglia, F; Metro, G; Spinelli, Gp; Banna, Gl; Friedlaender, A; Addeo, A; Ficorella, C; Porzio, G; Tiseo, M; Russano, M; Russo, A; Pinato, Dj.. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - 15:1(2022), p. 9. [10.1186/s13045-022-01226-2]
File in questo prodotto:
File Dimensione Formato  
Journal of Hematology & Oncology pubblicato 2022.pdf

accesso aperto

Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 2.18 MB
Formato Adobe PDF
2.18 MB Adobe PDF Visualizza/Apri
Journal of Hematology & Oncology pubblicato supplementary 2022.pdf

accesso aperto

Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 409.56 kB
Formato Adobe PDF
409.56 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2914168
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact